Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).

Pazo-Cid RA, Lanzuela M, Esquerdo G, Pérez-Gracia JL, Antón A, Amigo G, Trufero JM, García-Otín AL, Martín-Duque P.

Clin Transl Oncol. 2012 Aug;14(8):564-74. doi: 10.1007/s12094-012-0842-y. Epub 2012 Jul 18.

PMID:
22855137
2.

Clinical trials of antiangiogenic therapy for hepatocellular carcinoma.

Taketomi A.

Int J Clin Oncol. 2016 Apr;21(2):213-218. doi: 10.1007/s10147-016-0966-0. Epub 2016 Feb 22. Review.

PMID:
26899258
3.

Antiangiogenic therapies for advanced hepatocellular carcinoma.

Sampat KR, O'Neil B.

Oncologist. 2013;18(4):430-8. doi: 10.1634/theoncologist.2012-0388. Epub 2013 Apr 10. Review.

4.

Targeted agents and systemic therapy in hepatocellular carcinoma.

Ang C, O'Reilly EM, Abou-Alfa GK.

Recent Results Cancer Res. 2013;190:225-46. doi: 10.1007/978-3-642-16037-0_15. Review.

PMID:
22941024
5.

Novel drugs in clinical development for hepatocellular carcinoma.

Waidmann O, Trojan J.

Expert Opin Investig Drugs. 2015;24(8):1075-82. doi: 10.1517/13543784.2015.1058776. Epub 2015 Jun 24. Review.

PMID:
26108356
6.

Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?

Faivre S, de Gramont A, Raymond E.

Target Oncol. 2016 Aug;11(4):565-7. doi: 10.1007/s11523-016-0427-8. No abstract available.

PMID:
26996978
7.

Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.

Gadaleta-Caldarola G, Divella R, Mazzocca A, Infusino S, Ferraro E, Filippelli G, Daniele A, Sabbà C, Abbate I, Brandi M.

Future Oncol. 2015;11(16):2263-6. doi: 10.2217/fon.15.161. No abstract available.

PMID:
26260805
8.

Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma.

Kuczynski EA, Kerbel RS.

Chin J Cancer. 2016 Nov 25;35(1):97.

9.

Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.

Han P, Li H, Jiang X, Zhai B, Tan G, Zhao D, Qiao H, Liu B, Jiang H, Sun X.

Mol Oncol. 2017 Mar;11(3):320-334. doi: 10.1002/1878-0261.12039. Epub 2017 Feb 17.

10.

Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.

Kuczynski EA, Yin M, Bar-Zion A, Lee CR, Butz H, Man S, Daley F, Vermeulen PB, Yousef GM, Foster FS, Reynolds AR, Kerbel RS.

J Natl Cancer Inst. 2016 Apr 8;108(8). doi: 10.1093/jnci/djw030. Print 2016 Aug.

11.

Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.

Weintraub JL, Salem R.

J Vasc Interv Radiol. 2013 Aug;24(8):1123-34. doi: 10.1016/j.jvir.2013.01.494. Epub 2013 Apr 4. Review.

PMID:
23562168
12.

The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?

Abou-Alfa GK, Venook AP.

Lancet Oncol. 2013 Jun;14(7):e283-8. doi: 10.1016/S1470-2045(13)70161-X.

PMID:
23725711
13.

Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.

Liu JY, Chiang T, Liu CH, Chern GG, Lin TT, Gao DY, Chen Y.

Mol Ther. 2015 Nov;23(11):1772-1782. doi: 10.1038/mt.2015.147. Epub 2015 Aug 17.

14.

Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.

Kudo M.

Oncology. 2017;92 Suppl 1:50-62. doi: 10.1159/000451016. Epub 2017 Feb 2. Review.

15.

Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.

Hollebecque A, Malka D, Ferté C, Ducreux M, Boige V.

Eur J Cancer. 2015 Feb;51(3):327-39. doi: 10.1016/j.ejca.2014.12.005. Epub 2015 Jan 2. Review.

PMID:
25559615
16.

Targeting angiogenesis in esophagogastric adenocarcinoma.

Okines AF, Reynolds AR, Cunningham D.

Oncologist. 2011;16(6):844-58. doi: 10.1634/theoncologist.2010-0387. Epub 2011 May 31. Review.

17.

Towards new tools for refined management of patients with advanced hepatocellular carcinoma under systemic therapy: some enthusiasm with a word of caution.

Piscaglia F, Cucchetti A, Dietrich CF, Salvatore V.

J Hepatol. 2013 Nov;59(5):924-5. doi: 10.1016/j.jhep.2013.07.028. Epub 2013 Aug 6. No abstract available.

18.

Systemic therapy of hepatocellular carcinoma: current and promising.

Kalyan A, Nimeiri H, Kulik L.

Clin Liver Dis. 2015 May;19(2):421-32. doi: 10.1016/j.cld.2015.01.009. Epub 2015 Mar 12. Review.

PMID:
25921671
19.

Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.

Finn RS, Zhu AX.

Expert Rev Anticancer Ther. 2009 Apr;9(4):503-9. doi: 10.1586/era.09.6. Review.

PMID:
19374603
20.

Supplemental Content

Support Center